

# Portugal

Business Plan

July 2022

Creating sustainable businesses that work with nature and provide solutions  
in health and balance to the world

# Disclaimers & Cautionary Statements

**TERMS OF USE AND DISCLAIMER** - This presentation is being provided for the sole purpose of providing the recipients with background information about Revitalize Earth (“Revitalize”). Revitalize has made reasonable efforts to ensure that the information contained in this presentation is accurate as of the date hereof, however, there may be inadvertent or unintentional errors. No representation, warranty or guarantee, express or implied, is made as to the fairness, accuracy, completeness or correctness of information contained in this presentation, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, results or statements in relation to future matters contained in this presentation. The views and information provided herein are based on a number of estimates and assumptions that are subject to significant business, economic, regulatory and competitive uncertainties. See “Forward Looking Statements” below. Revitalize is not liable to any recipient or third party for the use of or reliance on the information contained in this presentation. This presentation provides information in summary form only, is not intended to be complete and does not constitute an offer to sell or the solicitation of an offer to buy any security. It is not intended to be relied upon as advice to investors or potential investors and does not constitute a personal recommendation or take into account the investment objectives, financial situation or needs of any particular investor. Revitalize is not acting as agent or advisor and encourages the use of independent consultants, as necessary, prior to entering into transactions.

**FORWARD LOOKING STATEMENTS** - Certain of the information contained in this presentation may contain "*forward-looking information*". Forward-looking information and Statements may include, among others, statements regarding the future plans, costs, objectives or performance of the Company, or the assumptions underlying any of the foregoing. In this presentation, words such as "may", "would", "could", "will", "likely", "believe", "expect", "anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Forward-looking statements and information are based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company's control. These risks, uncertainties and assumptions include, but are not limited to, the Company's compliance with laws; changes in laws, regulations and guidelines; business strategy; risks inherent in strategic alliances and investments; competition; dependence upon key management personnel; conflicts of interest; operations in the United States; foreign investments; limited operating history; liquidity and additional financing; difficulty to forecast; fluctuations in cannabis prices; reputational risks to third parties; management of growth; anti-money laundering laws and regulation risks; anti-bribery law violations; litigation; cybersecurity risks; unknown defects and impairments; challenging global financial conditions; credit and liquidity risk; hedging risk; failure to obtain necessary licenses; governmental regulations; increased operation, regulatory and other risks; access to capital; operations in emerging markets; ability to forecast production; competitive conditions; the ability to acquire customers; constraints on the ability to market products; risks inherent in an agricultural business; wholesale price volatility; product recalls; product liability risks; environmental and employee health and safety regulations; reliance on key inputs; reliance on suppliers and skilled labour; inflation; intellectual property risks; insurance risks; vulnerability to rising energy costs; and transportation risks associated with the delivery of product. There may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. The Company does not intend, nor does the Company undertake any obligation, to update or revise any forward-looking information or statements contained in this presentation to reflect subsequent information, events or circumstances or otherwise, except if required by applicable laws. This presentation does not constitute an offer of shares for sale in the United States or to any person that is, or is acting for the account or benefit of, any U.S. person (as defined in Regulation S under the United States Securities Act of 1933, as amended, or in any other jurisdiction in which such an offer would be illegal. Revitalize shares have not been and will not be registered under the Securities Act.

# BACKGROUND

Focused on capitalizing on the growing worldwide demand of cannabis products, both the medical cannabis sector and the consumer market for cannabinoids (CBD, CBN and CBG, etc.).

Our focus is supplying the world with the best medicine on the planet We are using our sister company e-commerce site [Be Pain Free](#) to reach a global audience and setting up strategic locations for controlling the quality and supply chain. We are currently fulfilling from our farm in the U.S. and shipping direct to nearly 5,000 patients and consumers in 50 U.S. states. We will be expanding our e-commerce platform into Europe, supporting multiple languages and shipping from within the EU to all countries.

Due to the team experience of our parent company in the U.S., Revitalise Earth which will be the SPV in Portugal owning shares in the medical cannabis project in the Algarve.



Helvetia Finvest B.V the financiers also see the Portuguese project as a major stepping stone for the core team into the European market which is expected to grow exponentially over the next 5 years.

Helvetia is also launching a cannabis fund based in Luxembourg to get a foothold into this ever expanding market. Part of the core Revitalise Earth team are acting as consultants to the fund.

# PORTUGAL

Portugal is gearing up to become a medical marijuana production powerhouse serving growing European markets.

Only a handful of firms are currently fully operational and licensed to grow cannabis in Portugal. Most are in the process of obtaining a license. Portugal enjoys some of the lowest production costs in the world thanks in part to its temperate climate and natural light conditions.

It has been reported that there are currently 20 business activities licensed by the Portuguese medicines authority Infarmed, with an additional 99 licensing requests pending for activities to grow, manufacture, import and export cannabis for medicinal purposes.

According to local industry sources obtaining a license requires considerable paperwork: "We are the paperwork country and the license issuer, Infarmed doesn't care about the green rush. It's a health agency that doesn't take any unnecessary risks".

Our unique selling proposition - Cannabis biological makeup

is incredibly diverse and potential benefits with terpenes are no exception, there are over 2,000 different identified.

These terpenes are where the future market will be due to the fact they act as cannabinoids and are a major component in medicinal products.

It is crucial for the sister retail business, [Be Pain Free Global](#), to have controlled farming supply for maintaining product quality.




# REAL ESTATE

1,500 acres of land has been leased and will be initially cultivating THC cannabis on 10 acres. We will look to plant 2,000 plants per acre, with each acre estimated to produce approximately 6,000 lbs. (2,722 kg). There is the potential in the future to cultivate three crops per year due to the climate and soil quality.

Looking to the future, we will be more focused on oil refining as we see higher rates of success with our U.S. patients, when compared to flowers.

## Security

Particular attention will be given to investment in security to ensure complete safety of the operation. The cultivation facility will be fully monitored and have 24 hour security. Equipment for the identification and registration of all movement of personnel and access to areas of the product and derivatives will be installed.




# TERPENES

These valuable compounds unite the cannabis, health, wellness, and flavour industries with a wide range of benefits and applications. As of 2020, there have been over 100 cannabis-derived terpenes identified in published journals. Cannabis is one of the most abundant sources of terpenes in the entire world, with many compounds yet to be discovered. We know after studying hundred marijuana samples that there are over 400 terpenes and aroma compounds in a variety of strains.

In the world of cannabis, terpenes play a vital role in differentiating the flavour, aroma, and effects of specific cannabis strains. Terpenes help modulate the effects of the cannabinoids (CBD) and impact the entourage effect. Some of these terpenes may actually be considered a cannabinoid and enhance the efficacy of product formulations. When speaking of "effects", we are referring to some terpenes doing wonders for relaxation, others for stress relief, and others for energy and focus.

However the process to extract CBD from the whole plant material removes terpenes, so companies often reintroduce terpenes into their final products. Unfortunately, supply is limited and costly. Balance this with consumers increasingly seeking products with full terpene and cannabinoid profiles, often referred to as full spectrum. This explains the forecast growth of CAGR of 17.5% from \$4.8b in 2019 to \$28.5b by 2027. Source: Grand View Research



# ROUTE TO MARKET

Cannabis Terpenes have no legal restrictions so therefore have global market potential. There are two segments in Europe; essential oils, at the moment CBD market size is \$3.42B\* and the medical cannabis industry has a market size \$4.96B\* and growing (\*Data Bridge Market Research – report published Jan/22).



By extracting all flower to oil and remove the THC profitability increases by a factor of three. The oil products called “broad spectrum”. The isolated THC would be sold to pharmaceutical companies and countries that are sourcing from medical licensed companies. There are many countries that buy wholesale flower; Germany, Israel, Denmark and Netherlands for example.

## EUROPE


With a manufacturing and distribution hub in Europe we have the flexibility to adjust the end product to different law structures with the Eli, for example we can remove Delta 9 THC and sell that to the relevant market. The license (see appendix) allows us to grow any strain, meaning cultivation can be adjusted to the best market worldwide.

## USA

Currently wholesale cannabis terpenes are difficult to source. We will use intelligent pricing to assist us in expanding our reach in the wholesale market in California and Oregon.



# WORLDWIDE LEGAL STATUS



Source:

- (1) The Thailand National Legislative Assembly
- (2) Cowen Equity Research – Cannabis: \$75B Opportunity; Category Cross-Currents Keep Us Cautious on Booze
- (3) Marijuana Business Daily – An Overview of Cannabis Legalization around the World

# OUR KEY TEAM



**Ryan Swetits**

Chief Executive

Established MedicineMan in California 2017. Over 10 years experience in cannabis, agronomy and cultivation. Previously 82nd Airborne US-Army.



**Saleem Sarwar**

Vice President

20 years international experience in developing and operating successful businesses. Previously head of commodity trading, London.



**Abraham Sadian**

Manufacturing and Extraction

Degree in Biochemistry from Northridge. Specialist in Cannabis and Cancer.

# TEAM



**Pedro Hilario**

Legal Council

Specialist in company and commercial Law, civil contracts, foreign and real estate Law and investment. Regulatory and Pharmaceutical Law.



**Lynn Alison  
Bornfriend M.D**

Medical Advisor

Director of Psychiatric Services. Cancer Treatment Centers. Medical Advisory to PharmaCannis



**Scott B. Welts Esq**

Lawyer

Ex state Prosecutor,  
Specialist in U.S.  
Cannabis law

# APPENDIX

Hemp" (or the Portuguese "cânhamo") is a non controlled drug/pharmaceutical product (it falls under agriculture and industrial rules), as long as the THC levels remain under 0,2%. That is to say, according to European legislation (and abundant jurisprudence of the European Court of Justice), this is out of the scope of controlled drugs Hemp is an agricultural and industrial product, out of the scope and competence of drug enforcement laws and the pharmaceutical regulator (INFARMED, LP). THE QUESTION THAT IS RELEVANT IS THE EXACT OPOSITE: those who are currently (and there are plenty) producing CBD products are trading these as cannabis" products, are in fact NOT licensed by the relevant drug enforcement agencies, an are therefore UNDER SCRUTINY in case higher THC levels are found in their products This is a felony criminal offence by the way, if their products are found to have THC levels higher than 0%.

1. Portugal, as part of the EU, has enacted (since) 1993, drug enforcement laws, These laws set out the regime for criminal provisions on drugs AND the frame of licensing the production of legal of drugs.

2. All relevant Portuguese Laws refer in general terms to "cannabis plant" (including the most recent Law 33/2018 of 18th July AND Decree-Law 8/2019 of 15th Jan, ruling the legal frame for the use of "medication, substances and pharmaceutical prescription of cannabis plant based products")

This means whatever the THC level above the referred threshold, on any type of cannabis plant (Which is why the drug laws refer to it simply as "cannabis", regardless of the variety), falls into this laws. The legal licensing procedure with INFARMED is intended for legal markets of psychotropic drugs/ psychotropic substances".

3, The official version of Decree-Law 15/1993 (duly updated and noted). Here you will find "cannabis", referred to simply as such ("cannabis plant"), and in all forms, referred under substances Schedule I-C (if TCH levels in any cannabis plant falls under 0,2% THC they simply are NOT drug controlled substances and INFARMED does not have any power of authority on it).

4. A word on the species of the plant: our application (as per ANNEX IV thereof) specifically applied, and was accepted, for all existing species/varieties of "cannabis" plant, we explicitly referred to Sativa, Ruderalis and Indica, though this was not mandatory;

5. Just to be clear: nor the THC level is at question at INFARMED, LP application NOR the plant species is or will be at question.

6. You will find this to be entirely compatible with the Portuguese Laws in force, INFARMED, I.P. procedures, our application, international LAW (Single Convention on Narcotic Drugs and other relevant agreements AND European Laws and jurisprudence of the European Court of Justice)

Pedro Ataide Hilário Advogado, R.L. | Law Office